Zobrazeno 1 - 10
of 52
pro vyhledávání: ''
Publikováno v:
Angiology. 70:305-316
Contrast-induced acute kidney injury (CI-AKI) is a common complication of iodinated contrast medium administration during cardiac catheterization. Statin treatment has been shown to be associated with reduced risk of CI-AKI; however, the results are
Autor:
Moses Elisaf, Theodosios D Filippatos
Publikováno v:
Angiology. 67:507-509
Statins are the cornerstone of lipid-lowering treatment in patients with or without type 2 diabetes. Prospective randomized clinical trials and meta-analyses have shown that the statin-mediated decrease in plasma low-density lipoprotein cholesterol (
Autor:
Osman Akın Serdar, Feyzullah Besli, Serhat Çalişkan, Cengiz Basar, Ufuk Polat, Fatih Gungoren
Publikováno v:
Angiology. 67(6)
Statins may exert pleiotropic effects in coronary artery disease (CAD), diabetes mellitus, and familial hypercholesterolemia. We evaluated the effects of statins on the neutrophil–lymphocyte ratio (NLR) and mean platelet volume (MPV) in 261 consecu
Autor:
Nikolaos Tsilimingas, Filippos Triposkiadis, Antigoni Lazou, Georgios I Tagarakis, Christos Voucharas
Publikováno v:
Angiology. 63:416-419
We suggest a new, easily applicable way of myocardial hypertrophy induction in rats. Forty randomized age-matched male Wistar rats were divided into 2 groups of 20 each: a control group and an orally administered fludrocortisone/salt group. Myocardia
Autor:
Thomas F. Whayne
Publikováno v:
Angiology. 62:415-421
High cardiovascular risk patients need reduction of low-density-lipoprotein cholesterol (LDL-C) to
Autor:
Despina Perrea, Dimitri P. Mikhailidis, George Agrogiannis, Ioannis S. Vlachos, Kosmas I. Paraskevas, Dimitrios G. Iliopoulos, Dimitrios Tzivras, Alkistis Pantopoulou, Gabriel Karatzas
Publikováno v:
Angiology. 62:144-154
Background and Aim: The treatment-of-choice for the optimal management of the dyslipidemia of the metabolic syndrome (MetS) is not clearly defined. We compared the efficacy of 4 drug regimes for the management of this dyslipidemia in a mouse model. M
Autor:
Masaaki Inaba, Yutaka Furumitsu, Hideo Yasumoto, Masanori Emoto, Shuichi Jono, Takahiko Kawagishi, Yoshiki Nishizawa, Toshiaki Konishi, Atsushi Shioi, Katsuhito Mori, Tetsuo Shoji
Publikováno v:
Angiology. 61:86-91
Osteoprotegerin is a secretory glycoprotein. Recent experimental findings have suggested that osteoprotegerin may protect against vascular calcification and/or atherosclerosis. In humans, osteoprotegerin levels are positively correlated with the pres
Autor:
Georgios S. Goumas
Publikováno v:
Angiology. 60:93-98
Aggressive therapy with statins to lower the low density lipoprotein cholesterol decreases cardiovascular events. Nevertheless, administration of the highest approved statin dose only offers limited additional benefit at the expense of an increased i
Autor:
Hirotoshi Kamishirado, Tatsuhiro Tsuda, Terumi Hayashi, Kan Takayanagi, Teruo Inoue, Koichi Node, Masashi Sakuma
Publikováno v:
Angiology. 58:55-60
Experimental data and preliminary clinical studies suggest that lipid-lowering drugs might have a beneficial effect on restenosis after coronary angioplasty. Recently, statins have been focused on prevention of restenosis after coronary stent implant
Autor:
Basil M. RuDusky
Publikováno v:
Angiology. 56:295-304
Although aminophylline/theophylline has been relegated to third- and fourth-line status in the cardiopulmonary armamentarium, its use in specific pathophysiologic states, especially those of cardiac etiology, can be of significant benefit. The consul